Correlation of fibrinogen level with lipid profile in type 2 diabetes mellitus

Authors

  • Venkatesh Amalappa Desai Department of General Medicine, GIMS, Kalaburagi, Karnataka, India
  • Chandrakala . Department of General Medicine, KBNIMS, Kalaburagi, Karnataka, India
  • Anant A. Takalkar Department of Community Medicine, MIMSR Medical College and YCRH, Latur, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20201624

Keywords:

Fibrinogen, Lipid profile, Type II DM

Abstract

Background: Increasing evidence from epidemiological studies suggest that elevated plasma fibrinogen levels are associated with an increased risk of cardiovascular disorders especially in diabetic patients. Objective was to correlate fibrinogen levels in patients of type-2 diabetes mellitus with lipid profile.

Methods: It is a descriptive observational study conducted among type-2 diabetes mellitus patients at Khaja Bandanawaz Institute of Medical Sciences, Gulbarga in year 2011. Newly detected type-2 diabetic patients with and without associated hypertension of more than 40 years of age belonging to both sexes were included.

Results: Total 104 patients were involved in our study. Of which 75 were males and 29 females. There was a significant positive correlation between plasma cholesterol level and plasma fibrinogen level. The patients who had serum triglyceride level between 100-149 mg/dL had plasma fibrinogen level about 4.19±0.1 g/L and those with serum triglyceride level more than 400 mg/dL < had 9.01±0.83 g/L plasma fibrinogen level.  Significant positive correlation between serum triglyceride level and plasma fibrinogen level found. 36 patients with HDL level 35-39 mg/dL had plasma fibrinogen level of 5.9±1.50 g/L. So, there was a significant negative correlation between serum HDL and plasma fibrinogen level.

Conclusions: The present study showed positive correlation between serum cholesterol level, LDL level and triglyceride level with plasma fibrinogen levels. There was inverse relation with HDL level.

References

Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and micro vascular complications of Type 2 diabetes. Diab Care. 2001;24:2071-7.

Mazzone T. Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes. J Lab Clin Med. 2000;135:437-43.

Ginsberg HN, Goldberg LL. Disorders of lipoprotein metabolism. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison’s Principles of Internal Medicine. New York: McGraw Hill Medical Publishing Division; 2001:2246.

Harvey JN. Diabetic nephropathy. BMJ. 2002; 325:59-60.

Gupta P, Bhambani P, Narang S. Study of plasma fibrinogen level and its relation to glycemic control in type-2 diabetes mellitus patients attending diabetes clinic at a tertiary care teaching hospital in Madhya Pradesh, India. Int J Res Med Sci. 2016; 4:3748-54.

Bruno G, Cavallo-perin P, Bargero G, Borra M, Errico ND, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-Insulin-dependent diabetes mellitus. Ann Intern Med. 1996;125:653-7.

Anjula J, Gupta HL, Narayan S. Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. JAPI. 2001;49:227-30.

Ernst E, Ludwig KR. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of literature. Ann Intern Med. 1993;118:956-63

Gupta P, Bhambani P, Narang S. Study of plasma fibrinogen level and its relation to glycemic control in type-2 diabetes mellitus patients attending diabetes clinic at a tertiary care teaching hospital in Madhya Pradesh, India. Int J Res Med Sci. 2016; 4:3748-54

Ko GT, Chan JC, Tsang LL, Cockram CS. Hyperfibrinogenaemia did not improve after treating hyperglycaemia in Chinese type 2 diabetic patients. Ann Clini Biochem. 2000 Sep 1;37(5):655-61.

Ko GT, Yeung VT, Chan JC, Chow CC, Li JK, So WY, Tsang LW, Cockram CS. Plasma fibrinogen concentration in a Chinese population. Atherosclerosis. 1997 Jun 1;131(2):211-7.

Rankinen T, Hietanen E, Väisänen S, Lehtiö M, Penttilä I, Bouchard C, et al. Relationship between lipid peroxidation and plasma fibrinogen in middle-aged men. Throm Res. 2000 Sep 1;99(5):453-9.

Ganda OP, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabe Care. 1992 Oct 1;15(10):1245-50.

Resch KL, Ernst E. “Determinants of fibrinogen”, Biorrheol. 1995;154:3292-3.

Lazzari P, Cappellini A, Boari L, Madini G. “Fibrinogen in subjects with diabetes, impaired glucose tolerance and normal”, Atherosclerosis. Oct 1997;134(1-2):311-5

Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E. Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemosta. 1994 May;72(05):593-5.

Barazzoni R, Zanetti M, Davanzo G, Kiwanuka E, Carraro P, Tiengo A et al. “Increased fibrinogen production in type-2 diabetic patients without detectable vascular complications; Correlation with plasma glucagon concentration. J Clin End Metab. 2000;85(9):1321-5.

Downloads

Published

2020-04-23

Issue

Section

Original Research Articles